Table 1.
Baseline patient characteristics.
| All Patients | Lymphoma | Solid tumor stage I–III | Solid tumor stage IV | |
|---|---|---|---|---|
| Characteristics | n (% of 3638) | n (% of 534) | n (% of 2022) | n (% of 1050) |
| Age (years) | ||||
| <50 | 824 (22.6) | 117 (21.9) | 558 (27.6) | 142 (13.5) |
| 50–64 | 1430 (39.3) | 158 (29.6) | 854 (42.2) | 405 (38.6) |
| 65–69 | 465 (12.8) | 68 (12.7) | 212 (10.5) | 184 (17.5) |
| 70–74 | 409 (11.2) | 68 (12.7) | 192 (9.5) | 144 (13.7) |
| ≥75 | 510 (14.0) | 123 (23.0) | 206 (10.2) | 175 (16.7) |
| Race | ||||
| Caucasian | 3076 (84.6) | 475 (89) | 1682 (83.2) | 890 (84.8) |
| African–American | 373 (10.3) | 36 (6.7) | 215 (10.6) | 120 (11.4) |
| Other | 189 (5.2) | 23 (4.3) | 125 (6.2) | 40 (3.8) |
| ECOG PS | ||||
| 0 | 2047 (56.3) | 285 (53.4) | 1365 (67.5) | 379 (36.1) |
| 1 | 1297 (35.7) | 203 (38) | 578 (28.6) | 505 (48.1) |
| ≥2 | 294 (8.1) | 46 (8.6) | 79 (3.9) | 166 (15.8) |
| Baseline BSA | ||||
| ≤2 m2 | 2599 (71.4) | 321 (60.1) | 1520 (75.2) | 738 (70.3) |
| >2 m2 | 1039 (28.6) | 213 (39.9) | 502 (24.8) | 312 (29.7) |
| Medical history | ||||
| Prior chemotherapy | 847 (23.3) | 94 (17.6) | 289 (14.3) | 457 (43.5) |
| Recent surgery | 1205 (33.1) | 168 (31.5) | 837 (41.4) | 192 (18.3) |
| Diabetes | 409 (11.2) | 64 (12) | 196 (9.7) | 142 (13.5) |
| Cardiac disease | 205 (5.6) | 42 (7.9) | 87 (4.3) | 75 (7.1) |
| Lung disease | 317 (8.7) | 26 (4.9) | 145 (7.2) | 144 (13.7) |
| History of anemia | 598 (16.4) | 97 (18.2) | 249 (12.3) | 246 (23.4) |
| Chemotherapy treatment | ||||
| Anthracyclines | 1438 (39.5) | 368 (68.9) | 986 (48.8) | 74 (7.0) |
| Taxanes | 1048 (28.8) | 1 (0.2) | 605 (29.9) | 427 (40.7) |
| Platinums | 1150 (31.6) | 11 (2.1) | 558 (27.6) | 562 (53.5) |
| Two or more myelosuppressive drugs | 2963 (81.4) | 425 (79.6) | 1728 (85.5) | 780 (74.3) |
ECOG PS, eastern cooperative group performance status; BSA, body surface area.